BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

The poster is scheduled for presentation on May ... could become a best-in-class anticancer treatment with the potential to challenge the standard of care for NSCLC,” said MAIA CEO Vlad Vitoc ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its Trial in Progress abstract has been ...

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for ...

BriaCell's Phase 2 study also achieved a Clinical Benefit Rate (CBR) of 61%, outperforming ASCENT (40%) and TROPiCS-02 (34%), ...

Compugen Ltd. (NASDAQ: CGEN) Q1 2025 Earnings Call Transcript May 19, 2025 Compugen Ltd. misses on earnings expectations.

Meghan Markle, the Duchess of Sussex, has recently revealed that she embraced ancient Indian health practices during her ...

Data presented at the American Association for Cancer Research (AACR) AnnualMeeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous ...

ADC Therapeutics SA (NYSE: ADCT) Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings ...